HK1201747A1 - Chitosan covalently linked with small molecule integrin antagonist for targeted delivery - Google Patents
Chitosan covalently linked with small molecule integrin antagonist for targeted deliveryInfo
- Publication number
- HK1201747A1 HK1201747A1 HK15102355.8A HK15102355A HK1201747A1 HK 1201747 A1 HK1201747 A1 HK 1201747A1 HK 15102355 A HK15102355 A HK 15102355A HK 1201747 A1 HK1201747 A1 HK 1201747A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- small molecule
- covalently linked
- targeted delivery
- integrin antagonist
- molecule integrin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591293P | 2012-01-27 | 2012-01-27 | |
US201261670665P | 2012-07-12 | 2012-07-12 | |
PCT/EP2013/051279 WO2013110681A1 (en) | 2012-01-27 | 2013-01-24 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201747A1 true HK1201747A1 (en) | 2015-09-11 |
Family
ID=47603735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102355.8A HK1201747A1 (en) | 2012-01-27 | 2015-03-09 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
Country Status (12)
Country | Link |
---|---|
US (3) | US20130197205A1 (xx) |
EP (1) | EP2806896B1 (xx) |
JP (1) | JP6230199B2 (xx) |
KR (1) | KR20140120316A (xx) |
CN (1) | CN104039356B (xx) |
BR (1) | BR112014015753A8 (xx) |
CA (1) | CA2854251A1 (xx) |
DK (1) | DK2806896T3 (xx) |
HK (1) | HK1201747A1 (xx) |
MX (1) | MX2014008404A (xx) |
RU (1) | RU2014132564A (xx) |
WO (1) | WO2013110681A1 (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447035B2 (en) * | 2012-01-27 | 2016-09-20 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 |
US9487556B2 (en) | 2013-08-07 | 2016-11-08 | Arrowhead Pharmaceuticals, Inc. | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo |
EP3873900A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
CN112969687B (zh) | 2018-10-30 | 2024-08-23 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
WO2020092383A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN115073311B (zh) * | 2022-03-23 | 2023-05-23 | 河南大学 | 一种高效制备n,n′-二(2羟乙基)苯胺的合成方法 |
CN116693719A (zh) * | 2022-09-06 | 2023-09-05 | 湖南津安生物科技有限公司 | 一种新型的超高阳离子生物高分子及其合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US622901A (en) * | 1899-04-11 | Machine for making tufted fabrics | ||
US5486140A (en) | 1993-10-21 | 1996-01-23 | Venturedyne, Ltd. | Variable air volume terminal unit with exterior insulation |
SE9402528D0 (sv) | 1994-07-19 | 1994-07-19 | Astra Ab | Hårdvävnadsstimulerande med el |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
CA2662560A1 (en) | 2006-09-15 | 2008-03-20 | Fmc Biopolymer As | Oligonucleotide non-viral delivery systems |
KR100825519B1 (ko) | 2007-01-05 | 2008-04-25 | 주식회사 바이오폴리메드 | 키토산 기재 고분자 접합체 및 그 제조방법 |
EP2164964B1 (en) | 2007-07-06 | 2011-09-07 | Aarhus Universitet | Dehydrated chitosan nanoparticles |
ATE554170T1 (de) | 2007-07-23 | 2012-05-15 | Univ Aarhus | Nanopartikel-vermittelte behandlung für entzündungskrankheiten |
CN101293933B (zh) | 2008-06-17 | 2011-05-04 | 浙江大学 | 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用 |
PL2350043T3 (pl) | 2008-10-09 | 2014-09-30 | Tekmira Pharmaceuticals Corp | Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych |
US20120040004A1 (en) | 2009-01-28 | 2012-02-16 | Region Midtjylland | Treatment of radiation-induced fibrosis |
-
2013
- 2013-01-24 CN CN201380004563.1A patent/CN104039356B/zh active Active
- 2013-01-24 US US13/748,642 patent/US20130197205A1/en not_active Abandoned
- 2013-01-24 MX MX2014008404A patent/MX2014008404A/es unknown
- 2013-01-24 EP EP13701252.2A patent/EP2806896B1/en active Active
- 2013-01-24 RU RU2014132564A patent/RU2014132564A/ru not_active Application Discontinuation
- 2013-01-24 BR BR112014015753A patent/BR112014015753A8/pt not_active Application Discontinuation
- 2013-01-24 DK DK13701252.2T patent/DK2806896T3/en active
- 2013-01-24 KR KR1020147021109A patent/KR20140120316A/ko not_active Application Discontinuation
- 2013-01-24 CA CA2854251A patent/CA2854251A1/en not_active Abandoned
- 2013-01-24 US US14/373,669 patent/US20150306130A1/en not_active Abandoned
- 2013-01-24 JP JP2014553708A patent/JP6230199B2/ja active Active
- 2013-01-24 WO PCT/EP2013/051279 patent/WO2013110681A1/en active Application Filing
-
2015
- 2015-03-09 HK HK15102355.8A patent/HK1201747A1/xx unknown
-
2017
- 2017-11-14 US US15/812,406 patent/US11491178B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20140120316A (ko) | 2014-10-13 |
US20180099005A1 (en) | 2018-04-12 |
US20130197205A1 (en) | 2013-08-01 |
EP2806896A1 (en) | 2014-12-03 |
US20150306130A1 (en) | 2015-10-29 |
RU2014132564A (ru) | 2016-03-20 |
DK2806896T3 (en) | 2018-03-05 |
CN104039356B (zh) | 2018-08-17 |
MX2014008404A (es) | 2014-08-22 |
US11491178B2 (en) | 2022-11-08 |
WO2013110681A1 (en) | 2013-08-01 |
EP2806896B1 (en) | 2018-01-03 |
JP2015504958A (ja) | 2015-02-16 |
BR112014015753A8 (pt) | 2017-07-04 |
BR112014015753A2 (pt) | 2017-06-13 |
JP6230199B2 (ja) | 2017-11-15 |
CN104039356A (zh) | 2014-09-10 |
CA2854251A1 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268420A (en) | Oligonucleotide conjugates | |
HK1201747A1 (en) | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | |
EP2723393A4 (en) | EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES | |
HK1207388A1 (en) | Self-stabilizing linker conjugates | |
IL235608A (en) | Carriers for improved drug delivery | |
HK1205928A1 (en) | Ocular drug delivery system | |
GB201215193D0 (en) | Order delivery system | |
BR112014015195A2 (pt) | Artigo de entrega de fluxo | |
EP2896022A4 (en) | DRUG ADMINISTRATION REGULATOR | |
EP2683328A4 (en) | ADMINISTRATION SYSTEM | |
GB201121069D0 (en) | Delivery system | |
EP2793953A4 (en) | TELODENDRIMERS WITH INCREASED DRUG DELIVERY | |
EP2818140A4 (en) | STENT DELIVERY SYSTEM | |
BR112013028570A2 (pt) | nanopartículas poliméricas para administração de fármacos | |
EP2624798A4 (en) | ARTICLE COMPRISING A BENEFICIAL AGENT DISTRIBUTION SYSTEM FOR HEALTH | |
EP2683737A4 (en) | EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES | |
GB201217493D0 (en) | Delivery receptacles | |
ZA201309156B (en) | Drug delivery system | |
EP2670780A4 (en) | CELLULOSE-BASED NANOPARTICLES FOR DRUG DELIVERY | |
SG10201609440WA (en) | Multi-additive delivery system | |
IL235363A0 (en) | Means for releasing pesticides | |
PL2908837T3 (pl) | Kompozycje do dostarczania leku | |
EP2896401A4 (en) | TARGETED ACTIVE AGGREGATION SYSTEM FOR HEAVY-DUTY ACTIVE SUBSTANCE | |
EP2852378A4 (en) | COPOLYMER-XEROGEL NANOCOMPOSITES USEFUL FOR THE ADMINISTRATION OF MEDICAMENTS | |
ES1076172Y (es) | Cierre para vehiculo de reparto |